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SummAry – The aim of this study was to describe clinical effectiveness of azithromycin in 
the management of lower respiratory tract infections in daily clinical practice, to examine duration 
of symptoms after therapy initiation, and to record any possible adverse effects of azithromycin 
treatment. A total of 153 patients were included in the analysis of the effectiveness of azithromycin: 
94 patients with community acquired pneumonia (CAP) and 59 with acute exacerbation of chro-
nic bronchitis (AeCB). Clinical effectiveness was assessed as improvement, cure or failure after 
three-day treatment with azithromycin. The assessment was based on a calculation of clinical score 
for each diagnosis before treatment and on days 4, 10 and 28 after treatment initiation. Clinical 
effectiveness of azithromycin was 93.6% in CAP group and 94.9% in AeCB group. Azithromycin 
led to relief of symptoms within three days in 88.6% of CAP patients and 77.2% of AeCB patients. 
Overall, 15 adverse events were reported in 14 (9.1%) patients. The most common adverse events 
were abdominal pain, diarrhea and vomiting, each reported in four (2.6%) patients. Accordingly, 
azithromycin was found to have high clinical effectiveness and a small number of adverse events in 
the treatment of lower respiratory tract infections. iSrCtn38391551. 
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Introduction
Lower respiratory tract infections (Lrti) such 
as community acquired pneumonia (CAP) and acute 
exacerbation of chronic bronchitis (AeCB) are com-
mon diseases associated with significant morbidity 
and mortality rates1-7. A variety of bacterial species 
are associated with Lrti. The most common causes 
of CAP are Streptococcus (S.) pneumoniae, Mycoplasma 
(M.) pneumoniae, Chlamydia (C.) pneumoniae, Le-
gionella pneumophila, followed by viruses1. Their in-
cidence varies across different studies and regions, 
with S. pneumoniae and M. pneumoniae being most 
common8-10. more recently, two etiology trends have 
been observed in adult populations: patients older 
than 65 have more frequently pneumonia caused by 
S. pneumoniae, Haemophilus influenzae and respiratory 
viruses, while the population younger than 65 have 
more often CAP caused by M. pneumoniae3. M. pneu-
moniae is a very common pathogen in patients treated 
outpatiently and is also the most common pathogen 
in children and young adults10,11. in case of AeCB, 
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bacteria are associated with 50%-70% of infection-
related AeCB episodes, whereby the most common 
of them are H. influenzae, Moraxella catarrhalis and S. 
pneumoniae12-16. Some authors suggest that there are 3 
classes of pathogens involved in AeCB: 1) respiratory 
viruses (like influenza, parainfluenza and rhinovirus-
es), which are responsible for 30% of AeCB episodes; 
2) atypical bacteria (like C. pneumoniae), which are 
implicated in less than 10% of episodes; and 3) aero-
bic gram-positive and gram-negative bacteria (like 
Pseudomonas aeruginosa) in 40%-60% of episodes15.
due to the lack of rapid, reliable and cost-effective 
tests, the nature of disease and other practical prob-
lems in daily clinical practice, microbiology testing is 
rarely performed in outpatients. even if testing is per-
formed and the pathogen is identified, the information 
is available only after a few days or weeks. Therefore, 
patients with clinical symptoms of CAP and AeCB 
are treated with antimicrobials on an empiric basis in 
order to avoid the possible complications and deleteri-
ous consequences of Lrti. 
Azithromycin has proven to be an extremely ef-
ficacious antibiotic with expanded and enhanced 
antibacterial activity, prolonged and high tissue con-
centration, and low incidence of gastrointestinal side 
effects compared to similar antibiotics5,17-22. it has a 
short dosing period and low incidence of adverse drug 
reactions23-25. Azithromycin concentrations in spu-
tum, bronchial mucosa and alveolar macrophages are 
above the minimal inhibitory concentrations (miCs) 
for many pathogens for 4 days after a single dose 
administration24,25. in addition, its immunomodula-
tory activity has been recognized to be of increasing 
importance and might contribute to the overall thera-
peutic effect of azithromycin26.
The infectious diseases Society of America/
American Thoracic Society (idSA/AtS) recom-
mends azithromycin as monotherapy for the treat-
ment of CAP in previously healthy patients27, whereas 
the european Society of Clinical microbiology and 
infectious diseases (eSCmid) recommends it as an 
alternative treatment for outpatients28. in most of the 
countries, azithromycin is one of the recommended 
treatments for mild to moderate AeCB (defined as 
group 1 patients), whereas in some countries it is used 
as alternative29. in clinical trials, azithromycin showed 
to be either better or equally well tolerated, compared 
to other antibiotics5,20-23,30. in the last twenty years, re-
sistance of bacteria causing respiratory tract infections 
has increased, but reports on how it affects the results 
of treatment are scarce and controversial31. 
The present study describes clinical effectiveness 
of azithromycin therapy in outpatients, both children 
and adults, with a range of Lrti in the real world 
setting. furthermore, it examined the duration of 
symptoms after therapy initiation and the possible ad-
verse events.
Methods
Study design and patients
This was an international, multicenter, non-com-
parative study conducted in 23 centers in Croatia, 
macedonia and Bosnia and herzegovina. Outpatients 
were enrolled by their primary care physicians in the 
period from June 2008 to november 2009. Last pa-
tient finished the study in december 2009. The study 
protocol was reviewed and approved by ethics Com-
mittees and regulatory authorities in Croatia, mace-
donia and Bosnia and herzegovina. each patient and/
or patient’s parent/legal guardian signed an informed 
consent form before being included in the study. Out 
of 155 patients with Lrti included in the study, 154 
were included in the safety analysis and 153 in the ef-
fectiveness analysis.
Patients with clinical signs and symptoms of Lrti 
were consecutively included in the study according to 
the inclusion and exclusion criteria listed in table 1. 
The inclusion and exclusion criteria reflect patients 
who are usually treated by primary care physicians in 
the real world setting. Adult patients were treated with 
azithromycin 500 mg tablets once a day for three days. 
Children were treated with azithromycin 10 mg/kg/
day oral suspension for three days. if they were above 
50 kg of weight, they were given the adult dose. 
Study procedures 
On initial, baseline visit, complete medical history 
was taken and clinical examination conducted. Chest 
x-ray was obligatory for CAP patients, whereas it was 
optional for AeCB patients. furthermore, hematolog-
ic tests and sputum cultures were collected optionally, 
which is in accordance with the standard clinical prac-
tice in the countries involved, as well as with the idSA/
Acta Clin Croat,  Vol. 54,   No. 2,  2015 151
maja Gašparić et al. Azithromycin in lower respiratory tract infections
AtS guidelines. each patient received Patient diary in 
which patients or minor patients’ parents had to record 
the time of azithromycin administration over three 
days, body temperature (twice daily), adverse events, 
and time when they felt relief of signs and symptoms 
(one day, two days, three days or more than three days 
after therapy initiation). Patients were asked to bring 
completed diaries on the second visit (day 4). follow up 
visits were performed on days 4, 10 and 28. 
General and specific clinical signs and symptoms 
were recorded at each visit. Clinical score was calcu-
lated for each diagnosis, as presented in table 2. The 
sum of all scores gave a total clinical score, which was 
considered a measure for clinical findings at each visit. 
The maximum possible score for CAP was 20 at visit 1 
and 23 at other visits, whereas the maximum possible 
score for AeCB was 19 at all visits.
Clinical response to therapy was evaluated as 
cure (complete disappearance of signs and symptoms 
present at visit 1); improvement (defervescence with 
substantial reduction in the intensity of signs and 
symptoms present at visit 1; no need for additional 
antimicrobial therapy); failure (progression or recur-
rence of signs and symptoms and introduction of oth-
er antimicrobial therapy); or non-evaluable on days 10 
(visit 3) and 28 (visit 4). 
Table 1. Inclusion and exclusion criteria
Community acquired pneumonia (CAP) Acute exacerbation of chronic bronchitis (AECB)
Inclusion criteria Inclusion criteria
male or female outpatients•	
Acute onset of disease indicated by the presence of •	
fever 
Presence of at least 1 of the specific clinical signs •	
and symptoms such as cough, sputum production 
and chest pain;
X-ray confirmation of CAP •	
Signed informed consent form (for minors, par-•	
ent or legal guardian written consent needs to be 
obtained)
male or female outpatients•	
history of chronic bronchitis characterized by •	
cough and sputum production for more than two 
consecutive years and for most days in a consecutive 
three-month period in each year
Presence of at least 2 specific clinical signs and •	
symptoms such as intensification of preexisting 
dyspnea, increase in sputum volume, and sputum 
purulence
Signed informed consent form (for minors, par-•	
ent or legal guardian written consent needs to be 
obtained)
Exclusion criteria Exclusion criteria
hypersensitivity to macrolides •	
treatment with any antibiotic within 14 days prior •	
to enrolment
Participation in any clinical study within 4 weeks •	
prior to enrolment
Prior enrolment in this study  •	
Signs of sepsis based on the presence of at least 2 of •	
3 criteria: tachypnea (>20 breaths/min), tachycardia 
(>90 beats/min), hypothermia (<36 °C) or hyper-
thermia (>40 °C) 
Patients who need hospitalization and/or paren-•	
teral antibiotic therapy for CAP, as indicated by 
any of the following: respiratory frequency >20/
min, hypotension (systolic blood pressure <90 mm 
hg), disturbances of consciousness, oliguric/anuric 
patients, cyanotic patients
hypersensitivity to macrolides •	
treatment with any antibiotic within 14 days prior •	
to enrolment
Participation in any clinical study within 4 weeks •	
prior to enrolment
Prior enrolment in this study  •	
Signs of sepsis based on the presence of at least 2 of •	
3 criteria: tachypnea (>20 breaths/min), tachycardia 
(>90 beats/min), hypothermia (<36 °C) or hyper-
thermia (>40 °C) 
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Adverse events were recorded at all post-baseline 
visits. The adverse events reporting period com-
menced upon the subject’s entry in the study, defined 
as the time when the informed consent was obtained, 
and ended at the last visit. The severity, seriousness, 
causal relationship with study drug and outcome of an 
adverse event were also recorded. All serious adverse 
events were reported in accordance with the local reg-
ulatory requirements. 
Statistics
Categorical data were expressed in frequencies and 
relevant percentage. The significance of differences in 
frequencies between relevant subgroups was tested 
with the	 χ2-test or fisher’s exact test when appro-
priate. for continuous variables, we calculated mean 
values with standard deviations. differences between 
subgroups of interest were tested with wilcoxon rank-
sum test. The primary outcome variable included ef-
fectiveness and tolerability expressed as the number 
(percentage) of cured patients and number (percent-
age) of patients with adverse drug reactions. The sec-
ondary outcome variable was regression of symptoms 
assessed by total clinical score changes. The missing 
values of longitudinal variables that describe treatment 
effectiveness (presence or absence of symptoms or ac-
companying scores) were imputed following the last 
observation carried forward to avoid the bias of false-
positive results and preserve the power of the study. 
The generalized linear mixed effects model was used 
to assess factors independently influencing the clini-
cal score regression. effectiveness analysis was carried 
Table 2. Clinical score – effectiveness assessment
General clinical signs and symptoms
fever (daily peak)                     0-Absent  1 – (37.1-38 °C)    2- (38.1-39 °C)     3- (>39 °C)
Chills                                         0-Absent  1-Present
headache                                   0-Absent 1-Present
Cough                                        0-Absent  1-Present
rhinitis                                      0-Absent  1-Present
vomiting                                   0-Absent  1-Present
diarrhea 0-Absent  1-Present
inappetence                                0-Absent  1-Present
Specific clinical signs and symptoms
Community acquired pneumonia
Auscultatory findings 
at visit (v) 1 0-Absent   2-Present
Auscultatory findings 
at v2, v3 and v4 0-Absent
1-Present, but 







3-Purulent (thick, brown or 
green exudates)
Chest pain 0-Absent   2-Present
dyspnea   0-Absent   1-On exertion 2-On motion 3-At rest
Acute exacerbation of chronic bronchitis
intensification of 
pre-existing dyspnea 0-Absent   2-Present
dyspnea 0-Absent   1-On exertion 2-On motion 3-At rest
increase in sputum 
volume 0-Absent 2-Present
Sputum purulence 0-Absent 2-Present
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out on the intention-to-treat population (patients who 
had taken at least one dose of azithromycin and pre-
sented for at least one post-baseline visit). Safety data 
were analyzed on the safety population (confirmed to 
have taken at least one azithromycin dose). All analy-
ses were performed using SAS for windows, version 
9.2 (SAS institute inc., Cary, nC, uSA).
Results
A total of 153 patients with Lrti were included in 
the effectiveness analysis (94 patients with CAP and 
59 patients with AeCB). demographic and baseline 
characteristics are shown in table 3 and table 4.  
At the end of the study (day 28), azithromycin 
was efficacious in 93.6% (88/94) of CAP patients and 
94.9% (56/59) of AeCB patients. in the CAP group, 
cure was recorded in 85 patients and improvement in 
three patients at the end of the study. follow up chest 
x-ray was performed in 23 CAP patients. Complete 
regression was reported in 20 patients and partial re-
gression in three patients. in the AeCB group, 67.8% 
(40/59) of patients were cured, while improvement was 
observed in 27.1% (16/59) of patients at the end of the 
study (day 28). There were six failures recorded in the 
CAP group and three in the AeCB group (table 5). 
Clinical score based on the intensity of CAP and 
AeCB signs and symptoms was calculated for each pa-
tient. in the CAP group, the score at inclusion ranged 
between 4.0 and 17.0, median 8.0, suggesting mild to 
moderate intensity of symptoms. A significant drop of 
clinical score values occurred three days after treat-
ment initiation and the median clinical score was 0.0 at 
the end of the study. in the AeCB group, the median 
Table 3. Demographic and baseline data: community acquired pneumonia
Community acquired pneumonia 
(n=94)
Age (yrs), median (interquartile) 20.9   (0.3-79.9)
Gender, male (%) 59 (62.8%)
height (cm), median (interquartile) 157.5 (106.0-170.0)
weight (kg), median (interquartile) 50.0 (15.0-68.0)
Body mass index, median (interquartile) 20.7 (16.0-23.5)
Body temperature (ºC), median (interquartile) 37.9 (37.5-38.3)
heart rate (beats/min), median (interquartile) 85.0 (78.0-95.0)
respiratory rate (breaths/min), median (interquartile) 18.0 (16.0-19.0)
Systolic blood pressure (mm hg), median (interquartile) 120.0 (105.0-130.0)
diastolic blood pressure (mm hg), median (interquartile) 75.0 (70.0-80.0)
Auscultatory findings, n (%) 88 (93.6%)
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clinical score was 11.0 (range from 9.0 to 12.0) at base-
line. in 75% of patients, it was above or equal 11.0 at 
inclusion. A significant drop of clinical score values oc-
curred three days after treatment initiation, as shown in 
figure 1. At the end of the study, clinical score ranged 
from 0.0 to 1.0, median 0.0. The earliest treatment ef-
fect was observed as resolution of fever, which occurred 
within 48 hours of treatment in both groups. 
Antibiotics were taken by 48 (51.1%) CAP pa-
tients and 51 (86.4%) AeCB patients within a year 
Table 4. Demographic and baseline data: acute exacerbation of chronic bronchitis
Acute exacerbation of chronic bronchitis
(n=59)
Age (yrs), median (interquartile) 47.1   (2.8-84.3)
Gender, male (%) 28 (47.5%)
height (cm), median (interquartile) 165.0 (158.0-175.0)
weight (kg), median (interquartile) 71.0  (60.0-84.0)
Body mass index, median (interquartile) 25.3 (21.3-28.4)
Body temperature (ºC), median (interquartile) 37.8 (37.2-38.0)
heart rate (beats/min), median (interquartile) 80.0 (76.0-85.0)
respiratory rate (breaths/min), median (interquartile) 18.0 (126.0-19.0)
Systolic blood pressure (mm hg), median (interquartile) 130.0 (115.0-140.0)
diastolic blood pressure (mm hg), median (interquartile) 80.0 (70.0-85.0)








increase in sputum volume, n (%) 56 (94.9%)
Sputum purulence, n (%) 44 (74.6%)
Fig. 1. Clinical score values during the study.
Black boxes = community-acquired pneumonia; gray 
boxes = acute exacerbation of chronic bronchitis; EOTR = 
end of treatment (day 4); EOTH = end of therapy (day 
10); EOS = end of study (day 28)
Fig. 2. Cumulative percentage of patients experiencing 
relief of symptoms during azithromycin treatment.  
Day = day from therapy initiation; CAP = community 
acquired pneumonia; AECB = acute exacerbation of 
chronic bronchitis












































Diagnosis:   –––  Community acquired pneumonia   ......  Acute exacerbation of chronic bronchitis
Clinical score values during the study Cumulative percent of patients
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before inclusion in the study. median time of taking 
antibiotics before inclusion was 2.0 months (25th 75th 
percentile: 1.0 and 6.0 months) in the CAP group 
and 3.0 months (25th and 75th percentile: 2.0 and 5.0 
months) in the AeCB group. macrolides were taken 
by 15 (16.0%) CAP patients and 22 (37.3%) AeCB 
patients. median time of taking any macrolide was 5.5 
months (25th and 75th percentile: 2.0 and 6.0 months) 
in the CAP group and 6.0 months (25th and 75th per-
centile: 3.0 and 7.0 months) in the AeCB group. Pre-
vious use of macrolides or other antibiotics did not 
impact regression of the disease signs and symptoms 
in CAP patients (p=0.105 and p=0.512, respectively). 
The impact of previous use of macrolides or other an-
tibiotics in AeCB patients could not be assessed due 
to the low number of patients.
diaries were received from 91 CAP and 59 AeCB 
patients. Three patients in the CAP group and two 
in the AeCB group did not report their day of re-
lief. relief of symptoms was observed within three 
days of therapy initiation in 88.6% (78/88) of CAP 
patients and 77.2% (44/57) of AeCB patients (table 
4), which was in accordance with the drop of clinical 
score values shown in figure 1. figure 2 illustrates 
cumulative percentage of patients reporting symptom 
relief from the day of study inclusion. Comorbidities 
were present in 33.0% (31/94) of CAP patients and 
57.6% (34/59) of AeCB patients. hypertension was 
the most common comorbidity in both groups of pa-
tients. Concomitant therapy was reported by 77.0% 
(53/94) of CAP patients and 84.7% (50/59) of AeCB 
patients. Paracetamol was the most commonly taken 
drug in the CAP group (15.6% of patients), whereas 
aminophylline (11.2% of patients) and salbutamol 
(10.5% of patients) were the most commonly adminis-
tered drugs in the AeCB group.
Overall, 15 adverse events were reported in 14 
(9.1%) patients. Seven adverse events were charac-
terized as possibly, probably or definitely related to 
azithromycin. The most common adverse events were 
abdominal pain, diarrhea and vomiting, each report-
ed in four (2.6%) patients. Therapy was discontinued 
because of adverse events (nausea and vomiting) in 
one patient. two serious adverse events (requiring 
hospitalization) were reported; however, these events 
were not related to azithromycin therapy. These two 
patients were withdrawn from the study; they still re-
ceived a complete dose of azithromycin. 
Discussion 
Azithromycin showed high clinical effectiveness in 
the treatment of CAP and AeCB and led to relief of 
symptoms after three days in the majority of patients 
participating in this study. Such fast resolution of symp-
toms can be explained by pharmacokinetic properties 
of azithromycin and fast achievement of high tissue 
concentrations21,23-25, as well as by patient compliance 
to the three-day treatment regimen of azithromycin. 
furthermore, immunomodulatory activity of azithro-
mycin may also contribute to the overall clinical effec-
tiveness shown in this study26. high clinical effective-
ness observed in this study remained in the ranges of 
earlier clinical trials conducted more than 20 years ago. 
however, we must interpret the findings cautiously 
because these studies were randomized, double blind, 
comparative, and the etiology was confirmed5,18,20-23,30. 
There also are other factors that might contribute to the 












Cure 85 (90.4%) 40 (67.8%)
improvement 3 (3.2%) 16 (27.1%)
failure 6 (6.4%) 3 (5.1%)
Cumulative percent of patients with symptom relief 
upon inclusion
day 1 16 (18.2%) 3 (5.3%)
day 2 28 (31.8%) 11 (19.3%)
day 3 34 (38.6%) 30 (52.6%)
After >3 days 10 (11.4%) 13 (22.8%)
Clinical score values (median, 25th percentile and 75th 
percentile)
inclusion 8.0 (7.0-11.0) 11.0 (9.0-12.0)
day 4 4.0 (3.0-5.0) 4.0 (3.0-6.0)
day 10 1.0 (0.0-2.0) 1.0 (1.0-2.0)
day 28 0.0 (0.0-0.0) 0.0 (0.0-1.0)
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effectiveness of azithromycin, such as mild to moderate 
incidence of the disease in our patients, and also the 
possible viral etiology. however, according to the liter-
ature, viruses are responsible for significantly less CAP 
and AeCB than bacterial agents10,29. furthermore, in 
our study, pneumonia was confirmed by x-ray in all pa-
tients and about two-thirds of patients had signs and 
symptoms suggestive of bacterial infection, such as pu-
rulent sputum. 
Clinical effectiveness of azithromycin was high in 
the CAP group. This finding is consistent with a sys-
tematic review which confirms that azithromycin is 
the empiric choice for treatment when atypical pneu-
monia is suspected and is useful for mild and moder-
ate CAP caused by typical pathogens32. high clinical 
effectiveness of azithromycin was also confirmed in 
the group of patients with AeCB, where the majority 
of patients experienced relief of symptoms after three 
days of therapy. This is consistent with the results of 
the observational prospective study by milestone et al., 
which showed that patients with AeCB treated with 
a 3-day course of azithromycin experienced significant 
improvements in the health-related quality of life31. 
The majority of patients in the CAP group were 
younger (mean age 20.1), with a lower number of co-
morbidities (33.0%) and only a small proportion of 
patients (16.0%) used macrolides one year before in-
clusion. On the contrary, the AeCB group consisted 
of older patients (mean age 47.1 years) with more co-
morbidities (57.6% of patients) who used antibiotics, 
including macrolides, within one year before inclu-
sion more frequently (86.4% and 37.3%, respective-
ly). nevertheless, the cure and improvement rates of 
azithromycin were high in both groups, although the 
populations differed. we also compared resolution of 
clinical signs and symptoms in CAP patients based 
on previous treatment with antibiotics and specifically 
macrolides, and found that previous antimicrobial 
therapy had no impact on the resolution of signs and 
symptoms in CAP patients. 
This study was a non-comparative post-marketing 
observational study lacking confirmed etiology, which 
might be considered as a limitation of the study. On 
the other hand, studies of such a design resemble ev-
eryday clinical settings and provide insights into the 
“real-world” effectiveness of a drug. in this study, we 
demonstrated azithromycin to be efficacious in the 
treatment of CAP and AeCB in a “real-world” set-
ting. moreover, high clinical effectiveness was con-
firmed in both patient groups, although they were 
quite different according to age, comorbidities and 
previous antimicrobial treatment. The adverse drug 
reactions reported were in accordance with the ac-
knowledged safety profile of azithromycin. Therefore, 
we can conclude that azithromycin is a reliable anti-
biotic treatment for Lrti because of adequate cov-
erage, resulting in fast resolution of symptoms with 
little adverse drug reactions.
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Sažetak
SiGurnOSt i dJeLOtvOrnOSt AzitrOmiCinA u LiJeČenJu infeKCiJA dOnJih diŠnih 
PutOvA: meĐunArOdnA muLtiCentriČnA ne-uSPOredBenA StudiJA
M. Gašparić, A. Penezić, A. Kolumbić-Lakoš, D. Kovačić, M. Matrapazovski Kukuruzović i B. Baršić 
Ciljevi ove studije bili su opisati kliničku djelotvornost azitromicina u liječenju infekcija donjih dišnih putova u klinič-
koj praksi, ispitati trajanje simptoma nakon početka terapije te prikupiti podatke o neželjenim događajima. u ispitivanje 
su bila uključena 153 bolesnika: 94 bolesnika s pneumonijom iz opće populacije te 59 bolesnika s akutnom egzacerbacijom 
kroničnog bronhitisa. Klinička djelotvornost je ocijenjena kao poboljšanje, izliječenje ili neuspjeh liječenja trodnevnom 
terapijom azitromicinom. Procjena se osnivala na izračunu kliničkog indeksa za svaku dijagnozu prije početka terapije te 
nakon 4, 10 i 28 dana. u ovom ispitivanju klinička djelotvornost azitromicina bila je 93,6% u skupini bolesnika s pneu-
monijom iz opće populacije te 94,9% u bolesnika s akutnom egzacerbacijom kroničnog bronhitisa. Azitromicin je doveo 
do olakšanja simptoma unutar 3 dana kod 88,6% bolesnika s pneumonijom i 77,2% bolesnika s akutnom egzacerbacijom 
kroničnog bronhitisa. zabilježeno je 15 neželjenih događaja kod 14 (9,1%) bolesnika. najčešći neželjeni događaji su bili 
dijareja i povraćanje, od kojih je svaki zabilježen u 4 (2,6%) bolesnika. rezultati ispitivanja pokazuju da azitromicin ima 
visoku djelotvornost u liječenju infekcija donjih dišnih putova i izaziva mali broj nuspojava. iSrCtn38391551. 
Ključne riječi: Azitromicin – terapijska primjena; Ishod liječenja, procjena; Domicilne infekcije – farmakoterapija; Pneumoni-
ja – farmakoterapija; Bronhitis, kronični – farmakoterapija
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